5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
D000477:Alkylating Agents; D000577:Amides / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004247:DNA / Q000037:antagonists & inhibitors; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000188:drug therapy; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D051381:Rats; D012878:Skin Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014226:Triazenes / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000477:Alkylating Agents; D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014226:Triazenes; D004247:DNA